The Experts below are selected from a list of 261 Experts worldwide ranked by ideXlab platform
Brian S Buckley - One of the best experts on this subject based on the ideXlab platform.
-
antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short term catheterisation in hospital a multicentre randomised controlled trial
The Lancet, 2012Co-Authors: Robert Pickard, Graeme Maclennan, Kath Starr, Mary Kilonzo, Gladys Mcpherson, Katie Gillies, Alison Mcdonald, Katherine Walton, Brian S BuckleyAbstract:Summary Background Catheter-associated urinary tract infection (CAUTI) is a major preventable cause of harm for patients in hospital. We aimed to establish whether short-term routine use of antimicrobial catheters reduced risk of CAUTI compared with standard polytetrafluoroethylene (PTFE) catheterisation. Methods In our parallel, three group, multicentre, randomised controlled superiority trial, we enrolled adults (aged ≥16 years) requiring short-term (≤14 days) catheterisation at 24 hospitals in the UK. Participants were randomly allocated 1:1:1 with a remote computer allocation to receive a silver alloy-coated catheter, a Nitrofural-impregnated catheter, or a PTFE-coated catheter (control group). Patients undergoing unplanned catheterisation were also included and consent for participation was obtained retrospectively. Participants and trial staff were unmasked to treatment assignment. Data were collected by trial staff and by patient-reported questionnaires for 6 weeks after randomisation. The primary outcome was incidence of symptomatic urinary tract infection for which an antibiotic was prescribed by 6 weeks. We postulated that a 3·3% absolute reduction in CAUTI would represent sufficient benefit to recommend routine use of antimicrobial catheters. This study is registered, number ISRCTN75198618. Findings 708 (10%) of 7102 randomly allocated participants were not catheterised, did not confirm consent, or withdrew, and were not included in the primary analyses. Compared with 271 (12·6%) of 2144 participants in the control group, 263 (12·5%) of 2097 participants allocated a silver alloy catheter had the primary outcome (difference −0·1% [95% CI −2·4 to 2·2]), as did 228 (10·6%) of 2153 participants allocated a Nitrofural catheter (−2·1% [−4·2 to 0·1]). Rates of catheter-related discomfort were higher in the Nitrofural group than they were in the other groups. Interpretation Silver alloy-coated catheters were not effective for reduction of incidence of symptomatic CAUTI. The reduction we noted in CAUTI associated with Nitrofural-impregnated catheters was less than that regarded as clinically important. Routine use of antimicrobial-impregnated catheters is not supported by this trial. Funding UK National Institute for Health Research Health Technology Assessment Programme.
-
antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short term catheterisation in hospital a multicentre randomised controlled trial
The Lancet, 2012Co-Authors: Robert Pickard, Graeme Maclennan, Kath Starr, Mary Kilonzo, Gladys Mcpherson, Katie Gillies, Alison Mcdonald, Katherine Walton, Thomas B Lam, Brian S BuckleyAbstract:Summary Background Catheter-associated urinary tract infection (CAUTI) is a major preventable cause of harm for patients in hospital. We aimed to establish whether short-term routine use of antimicrobial catheters reduced risk of CAUTI compared with standard polytetrafluoroethylene (PTFE) catheterisation. Methods In our parallel, three group, multicentre, randomised controlled superiority trial, we enrolled adults (aged ≥16 years) requiring short-term (≤14 days) catheterisation at 24 hospitals in the UK. Participants were randomly allocated 1:1:1 with a remote computer allocation to receive a silver alloy-coated catheter, a Nitrofural-impregnated catheter, or a PTFE-coated catheter (control group). Patients undergoing unplanned catheterisation were also included and consent for participation was obtained retrospectively. Participants and trial staff were unmasked to treatment assignment. Data were collected by trial staff and by patient-reported questionnaires for 6 weeks after randomisation. The primary outcome was incidence of symptomatic urinary tract infection for which an antibiotic was prescribed by 6 weeks. We postulated that a 3·3% absolute reduction in CAUTI would represent sufficient benefit to recommend routine use of antimicrobial catheters. This study is registered, number ISRCTN75198618. Findings 708 (10%) of 7102 randomly allocated participants were not catheterised, did not confirm consent, or withdrew, and were not included in the primary analyses. Compared with 271 (12·6%) of 2144 participants in the control group, 263 (12·5%) of 2097 participants allocated a silver alloy catheter had the primary outcome (difference −0·1% [95% CI −2·4 to 2·2]), as did 228 (10·6%) of 2153 participants allocated a Nitrofural catheter (−2·1% [−4·2 to 0·1]). Rates of catheter-related discomfort were higher in the Nitrofural group than they were in the other groups. Interpretation Silver alloy-coated catheters were not effective for reduction of incidence of symptomatic CAUTI. The reduction we noted in CAUTI associated with Nitrofural-impregnated catheters was less than that regarded as clinically important. Routine use of antimicrobial-impregnated catheters is not supported by this trial. Funding UK National Institute for Health Research Health Technology Assessment Programme.
Victor Martinezmerino - One of the best experts on this subject based on the ideXlab platform.
-
design synthesis and biological evaluation of new potent 5 nitrofuryl derivatives as anti trypanosoma cruzi agents studies of trypanothione binding site of trypanothione reductase as target for rational design
European Journal of Medicinal Chemistry, 2004Co-Authors: Gabriela Aguirre, Eliana Cabrera, Hugo Cerecetto, Rossanna Di Maio, Mercedes Gonzalez, Gustavo Seoane, Adelina Duffaut, Ana Denicola, Victor MartinezmerinoAbstract:Abstract Design, using force-field calculations on the catalytic site of trypanothione reductase from Trypanosoma cruzi , has led to the development of new 5-nitrofuryl derivatives as potential anti-trypanosomal agents. The synthesized compounds were tested in vitro against T. cruzi and more than 75% of the prepared derivatives showed higher activity than nifurtimox. Compounds 5 and 11 , hexyl 4-(5-nitrofurfurylidene)carbazate and N -hexyl 3-(5-nitrofuryl)propenamide, showed the highest in vitro trypanocidal effect reported to date for members of the nitrofuran family. Partition coefficients and energies for the single-electron reduction of compounds were theoretically determined. These properties could be not the major cause of the activities’ differences. The physicochemical environment around E19, W22, C53 and Y111 residues within the trypanothione binding site of trypanothione reductase resulted a valuable target for the rational design of anti-trypanosomal drugs.
Antonia Tdo Amaral - One of the best experts on this subject based on the ideXlab platform.
-
investigation of 5 nitrofuran derivatives synthesis antibacterial activity and quantitative structure activity relationships
Journal of Medicinal Chemistry, 2001Co-Authors: J R M Pires, C Saito, Suely Lopes Gomes, Astrea M Giesbrecht, Antonia Tdo AmaralAbstract:Three sets of antibacterial nitrofuran derivatives [set I, 5-R-substituted (Z)-2-(5-nitrofuran-2-ylmethylene)-3(2H)-benzofuranones (R = OCH3, H, CH3, C2H5, nC3H7, Cl, Br, CN, and NO2) and their 2-hydroxyphenyl and 2-acetoxyphenyl analogues; set II, 5-R-substituted (E)-1-(2-hydroxyphenyl)-3-(5-nitrofuryl)-2-propen-1-ones (R = H, CH3, C2H5, Cl, and NO2); and set III, 5-R-substituted (E)-1-(2-acetoxyphenyl)-3-(5-nitrofuryl)-2-propen-1-ones (R = H, CH3; C2H5, Cl, and NO2)] were prepared and tested against a Gram-positive (Staphylococcus aureus, strain ATCC-25923) and a Gram-negative bacterium (Caulobacter crescentus, strain NA 1000). QSAR equations derived for the IC50 values against both bacteria show negative contributions of two terms: an electronic one, expressed either by σ, the Hammett substituent constant, or by E, the cyclic voltametric reduction potential. Another term described by an indicator variable, Iabs, is assigned the value of 0 for set I compounds and the value of 1 for sets II and III. No ...
Ana Denicola - One of the best experts on this subject based on the ideXlab platform.
-
novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes dna and redox metabolism as potential therapeutic targets
Journal of Medicinal Chemistry, 2006Co-Authors: Lucia Otero, Ana Denicola, Juan Diego Maya, Antonio Morello, Marisol Vieites, Lucia Boiani, Carolina Rigol, Lucia Opazo, Claudio Oleaazar, Luise R KrauthsiegelAbstract:In the search for new therapeutic tools against American Trypanosomiasis palladium complexes with bioactive nitrofuran-containing thiosemicarbazones as ligands were obtained. Sixteen novel palladium (II) complexes with the formulas [PdCl2(HL)] and [Pd(L)2] were synthesized, and the crystal structure of [Pd(5-nitrofuryl-3-acroleine thiosemicarbazone)2]·3DMSO was solved by X-ray diffraction methods. Most complexes showed higher in vitro growth inhibition activity against Trypanosoma cruzi than the standard drug Nifurtimox. In most cases, the activity of the ligand was maintained or even increased as a result of palladium complexation. In addition, the complexes' mode of antitrypanosomal action was investigated. Although the complexes showed strong DNA binding, all data strongly suggest that the main trypanocidal mechanism of action is the production of oxidative stress as a result of their bioreduction and extensive redox cycling. Moreover, the complexes were found to be irreversible inhibitors of trypanoth...
-
design synthesis and biological evaluation of new potent 5 nitrofuryl derivatives as anti trypanosoma cruzi agents studies of trypanothione binding site of trypanothione reductase as target for rational design
European Journal of Medicinal Chemistry, 2004Co-Authors: Gabriela Aguirre, Eliana Cabrera, Hugo Cerecetto, Rossanna Di Maio, Mercedes Gonzalez, Gustavo Seoane, Adelina Duffaut, Ana Denicola, Victor MartinezmerinoAbstract:Abstract Design, using force-field calculations on the catalytic site of trypanothione reductase from Trypanosoma cruzi , has led to the development of new 5-nitrofuryl derivatives as potential anti-trypanosomal agents. The synthesized compounds were tested in vitro against T. cruzi and more than 75% of the prepared derivatives showed higher activity than nifurtimox. Compounds 5 and 11 , hexyl 4-(5-nitrofurfurylidene)carbazate and N -hexyl 3-(5-nitrofuryl)propenamide, showed the highest in vitro trypanocidal effect reported to date for members of the nitrofuran family. Partition coefficients and energies for the single-electron reduction of compounds were theoretically determined. These properties could be not the major cause of the activities’ differences. The physicochemical environment around E19, W22, C53 and Y111 residues within the trypanothione binding site of trypanothione reductase resulted a valuable target for the rational design of anti-trypanosomal drugs.
Gabriela Aguirre - One of the best experts on this subject based on the ideXlab platform.
-
design synthesis and biological evaluation of new potent 5 nitrofuryl derivatives as anti trypanosoma cruzi agents studies of trypanothione binding site of trypanothione reductase as target for rational design
European Journal of Medicinal Chemistry, 2004Co-Authors: Gabriela Aguirre, Eliana Cabrera, Hugo Cerecetto, Rossanna Di Maio, Mercedes Gonzalez, Gustavo Seoane, Adelina Duffaut, Ana Denicola, Victor MartinezmerinoAbstract:Abstract Design, using force-field calculations on the catalytic site of trypanothione reductase from Trypanosoma cruzi , has led to the development of new 5-nitrofuryl derivatives as potential anti-trypanosomal agents. The synthesized compounds were tested in vitro against T. cruzi and more than 75% of the prepared derivatives showed higher activity than nifurtimox. Compounds 5 and 11 , hexyl 4-(5-nitrofurfurylidene)carbazate and N -hexyl 3-(5-nitrofuryl)propenamide, showed the highest in vitro trypanocidal effect reported to date for members of the nitrofuran family. Partition coefficients and energies for the single-electron reduction of compounds were theoretically determined. These properties could be not the major cause of the activities’ differences. The physicochemical environment around E19, W22, C53 and Y111 residues within the trypanothione binding site of trypanothione reductase resulted a valuable target for the rational design of anti-trypanosomal drugs.